Background Focal subtenon carboplatin injections have recently been used as a
presumably toxicity-free adjunct to systemic chemotherapy for intraocular retinoblastoma.
Objective To report our clinical experience with abnormal ocular motility in patients treated
with subtenon carboplatin chemotherapy. Methods We noted abnormal ocular motility in 10
consecutive patients with retinoblastoma who had received subtenon carboplatin. During
ocular manipulation under general anesthesia, we assessed their eyes by forced duction …